Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Minoxidil sulphation in human liver and platelets

A study of interindividual variability

  • 34 Accesses

  • 2 Citations

Summary

Minoxidil requires to be sulphated to exert its hypotensive effect. We report on interindividual variability in the rate of minoxidil sulphation in 118 specimens of human liver and in platelets obtained from 100 healthy subjects and 100 newborns.

The frequency distribution histogram of the hepatic activity of minoxidil sulphotransferase was positively skewed; the mean was 631 pmol · min−1 · mg−1. After logarithmic transformation of the enzyme activity, the frequency distribution histogram became symmetrical and did not significantly deviate from normality. The rate of minoxidil sulphation was not different in platelets from adults (0.74 pmol · min−1 · mg−1) and newborns (1.16 pmol · min−1 · mg−1). The frequency distribution histograms were positively skewed and the results of normal equivalent deviation analysis was compatible with the presence of at least two subgroups of sulphotransferase in liver and platelets.

Thus, two phenotypes of sulphotransferase exist in human liver and platelets, and the “extensive sulphator” phenotype contributes to skewing the frequency distribution. In platelets, the percentage of subjects that fall in the two subgroups is different at birth and in adulthood. This can explain the different shape of the frequency distribution in newborn and adult platelets and suggests that platelet minoxidil sulphotransferase undergoes modification after birth.

This is a preview of subscription content, log in to check access.

References

  1. Abenhaim L, Romain Y, Kuchel O (1981) Platelet phenolsulphotransferase and catecholamines: physiological and pathological variations in humans. Can J Physiol Pharmacol 59: 300–306

  2. Anderson RJ, Weinshilboum RM (1980) Phenolsulphotransferase in human tissues: radiochemical enzymatic assay and biochemical properties. Clin Chim Acta 103: 79–90

  3. Bliss CI (1967) Statistic in Biology, vol 1. McGraw-Hill, New York, pp 101–110

  4. Bonham Carter SM, Glover V, Sandler M, Gillman PK, Bridges PK (1981) Human platelets sulphotransferase: separate control of the two forms and activity range in depressive illness. Clin Chim Acta 117: 333–344

  5. Buhl AE, Waldon DJ, Kawabe TT, Holland JM (1989) Minoxidil stimulates mouse vibrissa follicles in organ culture. J Invest Dermatol 92: 315–320

  6. Campbell NCR, Van Loon JA, Weinshilboum RM (1987) Human liver phenol sulphotransferase: assay conditions, biochemical properties and partial purification of isoenzymes of the thermostable form. Biochem Pharmacol 36: 1435–1446

  7. Campese VM (1981) Minoxidil: a review of its pharmacological properties and therapeutic use. Drugs 22: 257–278

  8. Cappiello M, Giuliani L, Rane A, Pacifici GM (1991) Dopamine sulphotransferase is better developed than p-niytrophenol sulphotransferase in the human fetus. Dev Pharmacol Ther 16: 83–88

  9. Cappiello M, Giuliani L, Pacifici GM (1990) Differential distribution of phenol and catechol sulphotransferase in human liver and intestinal mucosa. Pharmacology 40: 69–76

  10. Dooley TP, Walker CJ, Hirshey SJ, Falany CN, Diani AR (1991) Localization of minoxidil sulphotransferase in rat liver and the outer root sheath of anagen pelage and vibrissa follicles. J Invest Dermatol 96: 65–70

  11. DuCharme DW, Freyburger WA, Graham BE, Carlson RG (1973) Pharmacological properties of minoxidil: a new hypotensive agent. J Pharmacol Exper Ther 184: 662–670

  12. Falany CN (1991) Molecular enzymology of human liver cytosolic sulphotransferases. Trends Pharmacol Sci 12: 255–259

  13. Falany NC, Kerl EA (1990) Sulphation of minoxidil by human liver phenol sulphotransferase. Biochem Pharmacol 40: 1027–1032

  14. Falany CN, Vazquez ME, Heroux JA, Roth JA (1990) Purification and characterization of human liver phenol-sulphating phenol sulphotransferase. Arch Biochem Biophys 278: 312–318

  15. Foldes A, Meek JL (1973) Rat brain phenolsulphotransferase partial purification and some properties. Biochim Biophys Acta 327: 365–374

  16. Gerber JG, Nies AS (1990) Antihypertensive agents and the drug therapy of hypertension. In: Goodman-Gilman A, Rall TW, Nies AS, Taylor P (eds) Goodman and Gilman's The Pharmacological Basis of Therapeutics. Pergamon Press, New York Oxford Sydney, pp 801

  17. Glover V, Less AJ, Ward C, Stern GM, Sandler M (1983) Platelet phenolsulphotransferase activity in Parkinson's disease. J Neural Transmission 57: 95–102

  18. Johnson GA, Baker CA (1987) Sulphation of minoxidil by human platelet sulphotransferase. Clin Chim Acta 169: 217–228

  19. Littlewood J, Glover V, Sandler M, Petty R, Peatfield R, Rose FC (1982) Platelet phenolsulphotransferase deficiency in dietary migraine. Lancet I: 983–986

  20. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with Folin phenol reagent. J Biol Chem 193: 265–275

  21. McCall JM, Aiken JW, Chidester CG, DuCharme DW, Wendling MG (1983) Pyrimidine and triazine 3-oxide sulphates: a new family of vasodilators. J Med Chem 26: 1791–1793

  22. Olsen EA, DeLong ER, Weiners MS (1986) Dose-response study of topical minoxidil in male pattern baldness. J Am Acad Dermatol 15: 30–37

  23. Pacifici GM, Franchi M, Colizzi C, Giuliani L, Rane A (1988) Sulphotransferase in humans: development and tissue distribution. Pharmacology 36: 411–419

  24. Price RA, Cox NJ, Spielman RS, Van Loon JV, Maidak BL, Weinshilboum RM (1988) Inheritance of human platelet thermostable phenol sulphotransferase (TL PST) activity. Gen Epidemiol 5: 1–15

  25. Reveley AM, Bonham Carter SM, Revely MA, Sandler M (1983) A genetic study of platelet phenol- sulphotransferase activity in normal and schizophrenic twins. J Psychiat Res 17: 303–307

  26. Romiti P, Giuliani L, Pacifici GM (1992) Interindividual variability in the N-sulphation of desipramine in human liver and platelets. 33: 17–23

  27. Shapiro SS, Wilk MD (1965) An analysis test for normality (complete samples). Biometrika 52: 591–611

  28. Sundaram RS, Szumlanski C, Otterness D, Van Loon JA, Weinshilboum RM (1989) Human intestinal phenol sulphotransferase: assay conditions, activity levels and partial purification of the thermolabile form. Drug Metab Dispos Biol Fate Chem 17: 255–264

  29. Temellini A, Giuliani L, Pacifici GM (1991) Interindividual variability in the glucuronidation and sulphation of ethinyloestradiol in human liver. Br J Clin Pharmacol 31: 661–664

  30. Thomas RC, Harpootlian H (1975) Metabolism of minoxidil, a new hypotensive agent. II. Biotransformation following oral administration to rats, dogs, and monkeys. J Pharm Sci 64: 1366–1371

  31. Thomas RC, Hsi RSP, Harpootlian H, Judy RW (1975) Metabolism of minoxidil, a new hypotensive agent. I. Absorption, distribution, and excretion following administration to rats, dogs, and monkeys. J Pharm Sci 64: 1360–1366

  32. Van Loon J, Weinshilboum RM (1984) Human platelet phenol sulphotransferase: familial variation in thermal stability of the TS form. Biochem Gen 22: 997–1014

  33. Weinshilboum RM (1986) Phenol sulphotransferases in humans: properties, regulation, and function. Fed Proc 45: 2223–2228

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Pacifici, G.M., Bigotti, R., Marchi, G. et al. Minoxidil sulphation in human liver and platelets. Eur J Clin Pharmacol 45, 337–341 (1993). https://doi.org/10.1007/BF00265951

Download citation

Key words

  • Minoxidil
  • sulphotransferase
  • liver
  • extrahepatic tissues
  • platelets
  • interindividual variability
  • adults
  • neonates